Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Accuray Continues To Turn It Around

As the distant #3 in the radiation oncology market, Accuray (NASDAQ:ARAY) already has a tough row to hoe and past issues with product reliability and present-day concerns about the cost effectiveness of its systems don't help matters. Even so, it looks like the new CyberKnife M6 and Tomo H products, coupled with operating cost improvements, are giving this company another chance at making a real go of it. The stock's nearly 20% jump since my last update has certainly taken some urgency out of the relative value call, but the pace of order improvements and the extent of skepticism about the company still offer arguments for a long position.

Beating On Multiple Lines

Accuray's fiscal fourth quarter was...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details